This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ikenoue, T. Articles by Omata, M. Search for Related Content PubMed PubMed Citation Articles by Ikenoue, T. Articles by Omata, M.

Functional Analysis of PIK3CA Gene Mutations in Human Colorectal Cancer

¹ Department of Gastroenterology, Graduate School of Medicine and ² Clinical Research Center, University of Tokyo Hospital, Bunkyo-ku; ³ Division of Gastroenterology, Institute for Adult Diseases, Asahi Life Foundation, Nishi-Shinjuku, Shinjuku-ku, Tokyo Japan; and ⁴ Division of Molecular Genetics, Institute for Enzyme Research, University of Tokushima, Tokushima City, Tokushima Japan

Requests for reprints: Fumihiko Kanai, Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Phone: 81-3-3815-5411; Fax: 81-3-3814-0021; E-mail: kanaif-int{at}h.u-tokyo.ac.jp.

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Mutations in the PIK3CA gene, which encodes the p110 catalytic subunit of phosphatidylinositol 3-kinase (PI3K), have been reported in human cancers, including colorectal cancer. Most of the mutations cluster at hotspots within the helical and kinase domains. Whereas H1047R, one of the hotspot mutants, is reported to have elevated lipid kinase activity, the functional consequences of other mutations have not been examined. In this study, we examined the effects of colon cancer–associated PIK3CA mutations on the lipid kinase activity in vitro, activation of the downstream targets Akt and p70S6K in vivo and NIH 3T3-transforming ability. Of eight mutations examined, all showed increased lipid kinase activity compared with wild-type p110. All the mutants strongly activated Akt and p70S6K compared with wild-type p110 as determined by immunoblotting using phospho-specific antibodies. These mutants also induced morphologic changes, loss of contact inhibition, and anchorage-independent growth of NIH 3T3 cells. The hotspot mutations examined in this study, E542K, E545K, and H1047R, all had high enzymatic and transforming activities. These results show that almost all the colon cancer–associated PIK3CA mutations are functionally active so that they are likely to be involved in carcinogenesis.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Phosphatidylinositol 3-kinases (PI3K) are a family of lipid kinases that regulate the signaling pathways involved in cell proliferation and survival, cell motility and adhesion, differentiation, cytoskeletal rearrangement, and intracellular trafficking (1).

Mammalian cells contain multiple isoforms of PI3Ks, which are subdivided into three classes (2). The class I PI3Ks comprise a p110 catalytic subunit and a regulatory adaptor subunit. The catalytic subunits are composed of several modular domains, and most PI3K members share four homologous regions: the catalytic lipid kinase domain, the helical domain, the C2 domain, and the Ras-binding domain (RBD), as well as the NH₂-terminal domain that interacts with the regulatory subunit (3, 4). The catalytic lipid kinase domain exhibits weak homology to protein kinases. The available structural data suggest that the helical domain serves as scaffolding for the other domains. The C2 domain is involved in phospholipid membrane binding.

Class I PI3Ks can be further subdivided into two groups based on their structure and mode of activation: class Ia and class Ib (2). Class Ia PI3Ks are primarily regulated downstream of receptors with intrinsic tyrosine kinase activity, or are associated with nonreceptor tyrosine kinases. The binding of p85 SH2 domains to specific phosphotyrosine residues within the receptors or other signaling proteins activates the PI3K and recruits the cytosolic complex to the plasma membrane. At the membrane, PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) and converts it to phosphatidylinositol-3,4,5-triphosphate (PIP3), which recruits the serine-threonine protein kinases Akt and PDK1 to the membrane. PDK1 consequently phosphorylates and activates Akt, which in turn regulates a number of downstream targets (1). Synergistic with this activation, class Ia PI3Ks are stimulated directly by GTP-bound Ras (5). The ability of activated Ras to stimulate PI3K is important in Ras transformation of mammalian cells and is essential in Ras-induced cytoskeletal reorganization (6).

The isolation of a retroviral oncogene, v-p3k, encoding a homologue of p110 established that PI3K has active role in oncogenic transformation (7). The overexpression of constitutively active p110 has been reported to transform murine and chicken cells (7–9). The oncogenic potential of PI3K is correlated with the activation of the downsteram target Akt, which can also induce transformation (10, 11). Oncogenic transformation by PI3K and Akt depends on downstream targets that control translation, such as p70S6K and eIF4E (12).

Recent findings support the involvement of PI3K in tumorigenesis. Aberrant activation of the PI3K/Akt pathway, including the PTEN mutation and Akt overexpression and gene amplification has been implicated in several human cancers (13, 14). Somatic mutations in the gene for the p85 regulatory subunit of PI3K (PIK3R1) have been reported in human colon and ovarian tumors (15). The copy number of the gene for the p110 catalytic subunit of PI3K (PIK3CA) is frequently increased in ovarian cancers, resulting in increased PIK3CA transcription, p110 protein expression, and PI3K activity (16).

Recently, a large-scale mutational analysis of the entire coding regions of all the major classes of PI3K revealed somatic mutations in the PIK3CA in a significant fraction (25-30%) of colorectal cancers, gastric cancers, and glioblastomas and in a smaller fraction (<10%) of breast and lung cancers (17). Another report revealed that the PIK3CA mutations were found in 40% of breast cancers and 7% of ovarian cancers (18). The mutations clustered in hotspots within the helical (exon 9) and kinase (exon 20) domains. In that study, H1047R, a hotspot mutation in the kinase domain, was shown to have an elevated kinase activity compared with the wild type. However, the functional consequences of the other mutations are poorly understood. In this study, we did the functional analyses of PIK3CA mutations within different domains.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Constructs. The NH₂-terminally Myc-tagged p110 expression vector pCMV6-Myc-p110 and constitutively active p110 expression vector pCMV6-iSH2p110 were kindly provided by Lewis C. Cantley (Harvard Medical School, Boston, MA). To construct the p110 expression vector with a neomycin-resistant gene, a KpnI/SacI-digested fragment containing Myc-p110 cDNA from pCMV6-Myc-p110 was cloned into KpnI/SacI-digested pCMV3 vector, which was kindly provided by Phillip T. Hawkins (Babraham Institute, Cambridge, United Kingdom). To construct expression vectors for cancer-associated p110 mutants (R38H, G106V, C420R, E453Q, E542K, E545K, M1043I, and H1047R), the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) was used according to the manufacturer's instructions. Mutations were verified by sequencing both strands of DNA in the region of interest.

Cell lines and transfection. NIH 3T3 cells were cultured in DMEM/10% FCS. Transfections were done using FuGENE6 transfection reagent (Roche Molecular Biochemicals, Indianapolis, IN) according to the manufacturer's instructions. To generate NIH 3T3 cells stably expressing the p110 wild type or mutants, the cells were maintained in growth medium containing 400 µg/mL geneticin (Invitrogen, Carlsbad, CA). Multiple geneticin-resistant colonies were then pooled (>50 colonies) for use in soft agar assays, as described previously (19).

Antibodies and reagents. Anti-p70 S6K monoclonal antibody (H-9) and protein A/G agarose were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-Myc monoclonal antibody (9B11) and anti-phospho-Akt, anti-Akt, and anti-phospho-p70 S6K polyclonal antibodies were purchased from Cell Signaling Technology (Beverly, MA). Anti-p85 monoclonal antibody was purchased from Upstate Biotechnology (Lake Placid, NY).

Immunoprecipitation and immunoblotting. HEK293T cells were grown in 3.5-cm dishes and transfected with 2 µg of Myc-tagged wild type or each mutant p110. Twenty-four hours after transfection, the cells were washed twice with ice-cold PBS and lysed in lysis buffer A [50 mmol/L Tris-HCl (pH 7.4); 1% NP40, 150 mmol/L NaCl; 1 mmol/L EDTA; 1 mmol/L phenylmethylsulfonyl fluoride; 1 mmol/L NaF; and 1 mmol/L Na₃VO₄, containing 1 µg/mL each of aprotinin, leupeptin, and pepstatin]. Myc-p110 was immunoprecipitated by anti-Myc coupled to protein A/G-agarose overnight at 4°C, subjected to SDS-PAGE, and transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA) as previously described (20). The membranes were blotted with anti-p85 antibody overnight at 4°C and then with peroxidase-conjugated secondary antibody for 1 hour at room temperature. The immunoreactive proteins were visualized using an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, Buckinghamshire, England) according to the manufacturer's instructions.

Lipid kinase assay. HEK293T cells in 10-cm dishes were transfected with 10 µg of p110 constructs. The cells were serum-starved for 24 hours and lysed with lysis buffer B [20 mmol/L Tris-HCl (pH 7.4), 1% NP40, 137 mmol/L NaCl, 1 mmol/L CaCl₂, 1 mmol/L MgCl₂, 0.1 mmol/L Na₃VO₄, and 1 mmol/L phenylmethylsulfonyl fluoride]. The cell lysates were immunoprecipitated with anti-Myc coupled to protein A/G-agarose for 3 hours at room temperature. The immune complex was washed thrice with wash I (PBS containing 1% NP40), thrice with wash II [100 mmol/L Tris-HCl (pH 7.5), 500 mmol/L LiCl, and 0.1 mmol/L Na₃VO₄], and twice with wash III [10 mmol/L Tris-HCl (pH 7.5), 100 mmol/L NaCl, 1 mmol/L EDTA, and 0.1 mmol/L Na₃VO₄]. The beads were resuspended in 70 µL of kinase buffer [8 mmol/L Tris-HCl (pH 7.5), 80 mmol/L NaCl, 0.8 mmol/L EDTA, 15 mmol/L MgCl₂, 180 µmol/L ATP, and 5 µCi [-³²P]ATP] and 10 µL of sonicated PI mixture [20 µg L--PI (Sigma, St. Louis, MO), 10 mmol/L Tris-HCl (pH 7.5), and 1 mmol/L EGTA] for 15 minutes at room temperature. The reaction was stopped by the adding of 20 µL of 8 mol/L HCl, mixed with 160 µL of CHCl₃/CH₃OH (1:1), and centrifuged. The lower organic phase was spotted on an oxalate-treated silica gel 60 TLC plate (Merck, Darmstadt, Germany) and developed in CHCl₃/CH₃OH/H₂O/NH₄OH (60:47:11.6:2). The plate was dried and visualized by autoradiography using an FLA 3000 image analyzer (Fuji Photo Film Co., Ltd., Tokyo, Japan).

Akt and p70 S6K activation assay. NIH 3T3 cells stably expressing p110 constructs were maintained in DMEM containing 0.1% serum for 12 hours and lysed in lysis buffer A. The cell lysates were analyzed by SDS-PAGE and immunoblotting using anti-phospho-Akt, anti-Akt, anti-phospho-p70 S6K, and anti-p70 S6K antibodies.

Focus formation assay. Focus formation assays were done as previously described (19, 20). Briefly, NIH 3T3 cells in 10-cm dishes were transfected with 0.5 µg of empty vector or p110 constructs, cultured in DMEM containing 5% FCS, and stained with crystal violet 14 days later; the number of transformed foci was counted.

Soft agar assay. Soft agar assays were done as previously described (19). Briefly, NIH 3T3 cells stably expressing p110 wild type or mutants were trypsinized, suspended in medium containing 0.3% agar and 10% FCS, and plated onto a bottom layer containing 0.6% agar. The cells were plated at a density of 3 x 10⁴ cells per 6-cm dish, and the number of colonies >0.5 mm in diameter was counted 14 days later.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
In vitro lipid kinase activity of p110 mutants. To clarify the functional consequences of cancer-related PIK3CA mutations, we first examined the lipid kinase activity of the eight different mutants found in colorectal cancers (Fig. 1A). As the structure of p110 has not been determined, we showed the putative three-dimensional location of the mutations examined here based on the reported structure of p110 (ref. 3; Fig. 1B). We could not show the location of the R38H, G106V, or C420R mutations because the structure of the region where they might be located has not yet been determined (3).

View larger version (40K): [in this window] [in a new window] [Download PPT slide]   Figure 1. A, PIK3CA mutations analyzed in this study. E542K, E545K, and H1047R are reportedly hotspot mutants (11). No cancer-associated RBD mutations have been reported. B, three-dimensional locations of mutations in the catalytic subunit of PI3K. The mutations E453Q, E542K, E545K, M1043I, and H1047R are drawn as red sticks in the ribbon diagram of p110 (3) using the open-source molecular modeling package PyMOL (http://www.pymol.org/). The domains of the catalytic subunit are colored as follows: Ras-binding domain (pink), C2 domain (blue), helical domain (green), N-lobe of catalytic domain (red), C-lobe of catalytic domain (yellow), ATP (cyan), stick and other regions including linker regions (gray).

View larger version (76K): [in this window] [in a new window] [Download PPT slide]   Figure 2. A, in vitro lipid kinase activity of p110 mutants. HEK293T cells were transfected with Myc-tagged p110 constructs. After 24 hours, the kinase activities of the immunoprecipitated Myc-p110 proteins were assayed as described in Materials and Methods. The reaction products were analyzed using TLC. Representative experiment. B, association of p110 mutants with p85. HEK293T cells were transiently transfected with empty vector, Myc-p110 wild type, or p85 binding domain mutants R38H and G106V. The cells were lysed, and Myc-tagged p110 was immunoprecipitated with anti-Myc antibody. The immunoprecipitated proteins were analyzed on immunoblots with anti-Myc or anti-p85 antibodies. Representative experiment.

Akt and p70S6K activation induced by p110 mutants in vivo. To examine whether the cancer-associated p110 mutants activate downstream components of PI3K signaling in vivo, we tested p110 mutation-induced activation of Akt and p70S6K, two well-defined PI3K downstream molecules. The protein extracts from NIH 3T3 cells stably expressing p110 mutants were probed with antibodies against phospho-Akt and phospho-p70S6K. As shown in Fig. 3, the phosphorylation of both Akt and p70S6K was elevated in all the p110 mutant-expressing cells compared with wild-type expressing cells. The elevated levels of phospho-Akt and phospho-p70S6K with the C2 domain mutant C420R, the helical domain mutants E542K and E545K, and the kinase domain mutant H1047R were much greater than the levels with the p85 binding domain mutant R38H.

View larger version (42K): [in this window] [in a new window] [Download PPT slide]   Figure 3. Activation of Akt and p70S6K in vivo by p110 mutants. NIH 3T3 cells stably expressing p110 mutants were grown in DMEM containing 0.1% serum. After 12 hours, cell lysates were analyzed using SDS-PAGE and immunoblotting with anti-phospho-Akt, anti-Akt, anti-phospho-p70 S6K, anti-p70 S6K, and anti-Myc antibodies.

Morphologic change induced by p110 mutants.

View larger version (28K): [in this window] [in a new window] [Download PPT slide]   Figure 4. A, morphology of NIH 3T3 cells stably expressing p110 mutants. The cells stably expressing empty vector, wild type, E545K, and H1047R p110 were cultured in medium containing 10% FCS. B, focus-forming ability of p110 mutants. NIH 3T3 cells were transiently transfected with the p110 constructs. The number of transformed foci was counted 14 days later. Columns, mean of three independent experiments; bars, ±SD. C, focus-forming ability of p110 mutants. NIH 3T3 cells were transiently transfected with the p110 constructs. The number of transformed foci was counted 14 days later. Columns, mean from three independent experiments; bars, ±SD.

Focus formation activity induced by p110 mutants.

Anchorage-independent growth induced by p110 mutants. We examined anchorage-independent growth induced by cancer-associated p110 mutants. NIH 3T3 cells stably expressing each mutant were seeded into soft agar, and their colony-forming abilities were determined 14 days later. The p110 mutant-expressing cells formed colonies in soft agar, whereas wild-type p110-expressing cells did not (Fig. 4C). However, the p110 mutants induced far fewer colonies than did oncogenic H-Ras or B-Raf (data not shown).

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
Most of the reported PIK3CA mutations in human cancers are in the helical or kinase domains, although some mutations have been reported in the p85 binding or C2 domains (17). A point mutation within the RBD, K227E, was shown to elevate the basal lipid kinase activity of PI3K, suggesting a direct influence of the RBD on the catalytic activity of PI3K; however, no RBD mutation has been reported in human cancers (17, 23). In this study, we analyzed the functional consequences of PIK3CA mutations found in colorectal cancers. We selected eight of the 36 reported mutations: the p85 binding domain mutations R38H and G106V, the C2 domain mutations C420R and E453Q, the helical domain mutations E542K and E545K, and the kinase domain mutations M1043I and H1047R (Fig. 1A). The H1047R mutation elevates basal lipid kinase activity compared with that of the wild type in vitro (17). In this study, all the other mutants examined also had elevated lipid kinase activity, suggesting that they act as gain-of-function mutations. The strength of the activity resulting from the mutations seemed unrelated to the domains in which they were located. However, hotspot mutations, such as E542K, E545K, and H1047R, have been shown to produce high activity.

In the helical domain, another hotspot mutation, Q546K, has been reported in addition to the E542K and E545K mutations (17). These residues are located between the hA1 and hB1 helices of the domain, based on the structure of p110 (ref. 3; Fig. 1B). Although the functions of the helical domain other than its scaffold function are unclear, our results suggest that amino acid substitutions that insert a positive charge into the region recruit the molecule to the membrane where it functions.

Besides the hotspot mutation H1047R, some mutations surrounding His¹⁰⁴⁷ have been reported in colorectal cancers (17). We showed that the M1043I mutation also elevated lipid kinase activity. Based on the structure of the kinase domain of PI3K, these mutations are located in the k11 helix in the kinase domain (Fig. 1B; ref. 3). As the k11 helix is positioned near the kinase activation loop on the surface of the enzyme between the k12 helix on one side and k10 on the other, amino acid substitutions in the k11 helix may affect the conformation of the kinase activation loop, leading to elevated activity. Other kinase domain mutations that affect Thr¹⁰²⁵ in the k10 helix have been reported (17). Although we did not examine their activities, it seems reasonable to speculate that these mutants have elevated lipid kinase activities owing to changes in the conformation of the activation loop.

Reported mutations within the p85 binding and C2 domains account for only a small fraction of the colon cancer associated PIK3CA mutations (<15%). The C2 domain is often involved in phospholipid membrane binding using three loops known as CBR1, CBR2, and CBR3. According to the amino acid sequences of p110ß and p110, CBR3 (residues 395-417 of p110) is particularly rich in basic residues that may be important for membrane binding. The C420R mutation, one of two C2 domain mutations examined in this study, has been reported in breast and colon cancers (17, 18). As the C420R mutation is located in the region of p110 that corresponds to CBR3 (residues 407-429 of p110), it may lead to increased membrane binding by shifting the polarity of the CBR3 to more basic. Perhaps, the E453Q mutation produces elevated lipid kinase activity by changing an acidic residue to a neutral one, leading to increased membrane binding.

In mammalian cells, the activity of the p110 monomer is inhibited by p85 at 30°C, a temperature at which p110 is stable. By contrast, p85 is considered an activator of p110 at 37°C, a temperature at which p110 is unstable, not by increasing basal lipid kinase activity but by stabilizing p110 (24). The p85 binding domain mutants that we examined had increased lipid kinase activity. Under our experimental conditions, at a temperature of 37°C, binding to p85 is likely to increase the activity of p110. However, these mutations did not increase the binding ability to p85 in our coimmunoprecipitation assays (Fig. 2B). Therefore, these mutations are unlikely to increase the lipid kinase activity by stabilizing the p110 monomer by increasing the binding affinity to p85. These mutations might increase the basal activity or stability of p110 regardless of the p85 binding ability.

The mutant proteins with higher lipid kinase activity induced Akt and p70S6K activation in vivo and NIH 3T3 transformation as determined using focus formation or colony formation assays. Although we cannot exclude the possibility that some of the reported mutations are chance passenger mutations, our results suggest that most of the cancer-associated PIK3CA mutations contribute to tumorigenesis via the up-regulation of lipid kinase activity. Whereas this article was under revision, Kang et al. made a similar observation that supports the oncogenic potential of the PIK3CA mutations found in human cancers (25).

K-Ras mutations are commonly observed in human colorectal cancers (26). As oncogenic Ras interacts with and activates PI3K (5), the activation of the PI3K signaling pathway via K-Ras or PIK3CA mutations was considered one of the most common mechanisms involved in colorectal carcinogenesis. In fact, the PI3K pathway is reportedly activated in colon cancer cells frequently (27). Therefore, p110, which is encoded by the PIK3CA gene, is a potential target for developing drugs to treat colon cancer.

	Acknowledgments

 
Grant support: Program for the Organization for Pharmaceutical Safety and Research and the Japanese Ministry of Education, Culture, Sports, Science, and Technology.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Drs. Lewis C. Cantley and Phillip T. Hawkins for providing the plasmids and Dr. Hiraku Ono for assistance with the lipid kinase assays.

Received 11/17/04. Revised 1/23/05. Accepted 3/18/05.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science (Wash DC) 2002;296:1655–7.[Abstract/Free Full Text]
2. Wymann MP, Zvelebil M, Laffargue M. Phosphoinositide 3-kinase signalling: which way to target? Trends Pharmacol Sci 2003;24:366–76.[CrossRef][Medline]
3. Walker EH, Perisic O, Ried C, Stephens L, Williams RL. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature (Lond) 1999;402:313–20.[CrossRef][Medline]
4. Djordjevic S, Driscoll PC. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases. Trends Biochem Sci 2002;27:426–32.[CrossRef][Medline]
5. Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (Lond) 1994;370:527–32.[CrossRef][Medline]
6. Rodriguez-Viciana P, Warne PH, Khwaja A, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997;89:457–67.[CrossRef][Medline]
7. Singh B, Reddy PG, Goberdhan A, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 2002;16:984–93.[Abstract/Free Full Text]
8. Chang HW, Aoki M, Fruman D, et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science (Wash DC) 1997;276:1848–50.[Abstract/Free Full Text]
9. Klippel A, Escobedo MA, Wachowicz MS, et al. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol 1998;18:5699–711.[Abstract/Free Full Text]
10. Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt PK. The Akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci U S A 1998;95:14950–5.[Abstract/Free Full Text]
11. Sakoda H, Gotoh Y, Katagiri H, et al. Differing roles of Akt and serum- and glucocorticoid-regulated kinase in glucose metabolism, DNA synthesis, and oncogenic activity. J Biol Chem 2003;278:25802–7.[Abstract/Free Full Text]
12. Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 2001;98:136–41.[Abstract/Free Full Text]
13. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002;2:489–501.[CrossRef][Medline]
14. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257–62.[CrossRef][Medline]
15. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3'-kinase p85 gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61:7426–9.[Abstract/Free Full Text]
16. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99–102.[CrossRef][Medline]
17. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science (Wash DC) 2004;304:554.[Free Full Text]
18. Campbell IG, Russell SE, Choong DYH, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678–81.[Abstract/Free Full Text]
19. Ikenoue T, Hikiba Y, Kanai F, et al. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor B pathway and cellular transformation. Cancer Res 2004;64:3428–35.[Abstract/Free Full Text]
20. Ikenoue T, Hikiba Y, Kanai F, et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003;63:8132–7.[Abstract/Free Full Text]
21. McFall A, Ulku A, Lambert QT, Kusa A, Rogers-Graham K, Der CJ. Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase. Mol Cell Biol 2001;21:5488–99.[Abstract/Free Full Text]
22. Cheng JQ, Altomare DA, Klein MA, et al. Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene 1997;14:2793–801.[CrossRef][Medline]
23. Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J 1996;15:2442–51.[Medline]
24. Yu J, Zhang Y, McIlroy J, et al. Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110 catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 1998;18:1379–87.[Abstract/Free Full Text]
25. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005;102:802–7.[Abstract/Free Full Text]
26. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682–9.[Abstract/Free Full Text]
27. Khaleghpour K, Li Y, Banville D, Yu Z, Shen SH. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 2004;25:241–8.[Abstract/Free Full Text]

This article has been cited by other articles:

				Y. He, L. J. Van't Veer, I. Mikolajewska-Hanclich, M.-L. F. van Velthuysen, E. C.M. Zeestraten, I. D. Nagtegaal, C. J.H. van de Velde, and C. A.M. Marijnen PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients Clin. Cancer Res., November 15, 2009; 15(22): 6956 - 6962. [Abstract] [Full Text] [PDF]

				C.-N. Qian, K. A. Furge, J. Knol, D. Huang, J. Chen, K. J. Dykema, E. J. Kort, A. Massie, S. K. Khoo, K. Vanden Beldt, et al. Activation of the PI3K/AKT Pathway Induces Urothelial Carcinoma of the Renal Pelvis: Identification in Human Tumors and Confirmation in Animal Models Cancer Res., November 1, 2009; 69(21): 8256 - 8264. [Abstract] [Full Text] [PDF]

				B. Markman, F. Atzori, J. Perez-Garcia, J. Tabernero, and J. Baselga Status of PI3K inhibition and biomarker development in cancer therapeutics Ann. Onc., August 27, 2009; (2009) mdp347v1. [Abstract] [Full Text] [PDF]

				K. Kalinsky, L. M. Jacks, A. Heguy, S. Patil, M. Drobnjak, U. K. Bhanot, C. V. Hedvat, T. A. Traina, D. Solit, W. Gerald, et al. PIK3CA Mutation Associates with Improved Outcome in Breast Cancer Clin. Cancer Res., August 15, 2009; 15(16): 5049 - 5059. [Abstract] [Full Text] [PDF]

				S. Ogino, K. Nosho, G. J. Kirkner, K. Shima, N. Irahara, S. Kure, A. T. Chan, J. A. Engelman, P. Kraft, L. C. Cantley, et al. PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer J. Clin. Oncol., March 20, 2009; 27(9): 1477 - 1484. [Abstract] [Full Text] [PDF]

				R. Sasaki, M. Narisawa-Saito, T. Yugawa, M. Fujita, H. Tashiro, H. Katabuchi, and T. Kiyono Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes Carcinogenesis, March 1, 2009; 30(3): 423 - 431. [Abstract] [Full Text] [PDF]

				J. P. Gustin, B. Karakas, M. B. Weiss, A. M. Abukhdeir, J. Lauring, J. P. Garay, D. Cosgrove, A. Tamaki, H. Konishi, Y. Konishi, et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways PNAS, February 24, 2009; 106(8): 2835 - 2840. [Abstract] [Full Text] [PDF]

				P. Laurent-Puig, A. Lievre, and H. Blons Mutations and Response to Epidermal Growth Factor Receptor Inhibitors Clin. Cancer Res., February 15, 2009; 15(4): 1133 - 1139. [Abstract] [Full Text] [PDF]

				E. Pencreach, E. Guerin, C. Nicolet, I. Lelong-Rebel, A.-C. Voegeli, P. Oudet, A. K. Larsen, M.-P. Gaub, and D. Guenot Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1{alpha} Axis Clin. Cancer Res., February 15, 2009; 15(4): 1297 - 1307. [Abstract] [Full Text] [PDF]

				H. Yamamoto, H. Shigematsu, M. Nomura, W. W. Lockwood, M. Sato, N. Okumura, J. Soh, M. Suzuki, I. I. Wistuba, K. M. Fong, et al. PIK3CA Mutations and Copy Number Gains in Human Lung Cancers Cancer Res., September 1, 2008; 68(17): 6913 - 6921. [Abstract] [Full Text] [PDF]

				L. Zhao and P. K. Vogt Helical domain and kinase domain mutations in p110{alpha} of phosphatidylinositol 3-kinase induce gain of function by different mechanisms PNAS, February 19, 2008; 105(7): 2652 - 2657. [Abstract] [Full Text] [PDF]

				C.-H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, S. B. Gabelli, and L. M. Amzel The Structure of a Human p110{alpha}/p85{alpha} Complex Elucidates the Effects of Oncogenic PI3K{alpha} Mutations Science, December 14, 2007; 318(5857): 1744 - 1748. [Abstract] [Full Text] [PDF]

				J. Shao, M.K. Washington, R. Saxena, and H. Sheng Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin Carcinogenesis, December 1, 2007; 28(12): 2476 - 2483. [Abstract] [Full Text] [PDF]

				M. Barbareschi, F. Buttitta, L. Felicioni, S. Cotrupi, F. Barassi, M. Del Grammastro, A. Ferro, P. Dalla Palma, E. Galligioni, and A. Marchetti Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas Clin. Cancer Res., October 15, 2007; 13(20): 6064 - 6069. [Abstract] [Full Text] [PDF]

				N. Miled, Y. Yan, W.-C. Hon, O. Perisic, M. Zvelebil, Y. Inbar, D. Schneidman-Duhovny, H. J. Wolfson, J. M. Backer, and R. L. Williams Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit Science, July 13, 2007; 317(5835): 239 - 242. [Abstract] [Full Text] [PDF]

				X.-N. Guo, A. Rajput, R. Rose, J. Hauser, A. Beko, K. Kuropatwinski, C. LeVea, R. M. Hoffman, M. G. Brattain, and J. Wang Mutant PIK3CA-Bearing Colon Cancer Cells Display Increased Metastasis in an Orthotopic Model Cancer Res., June 15, 2007; 67(12): 5851 - 5858. [Abstract] [Full Text] [PDF]

				M. Gymnopoulos, M.-A. Elsliger, and P. K. Vogt Rare cancer-specific mutations in PIK3CA show gain of function PNAS, March 27, 2007; 104(13): 5569 - 5574. [Abstract] [Full Text] [PDF]

				T. Morita, A. Yamashita, I. Kashima, K. Ogata, S. Ishiura, and S. Ohno Distant N- and C-terminal Domains Are Required for Intrinsic Kinase Activity of SMG-1, a Critical Component of Nonsense-mediated mRNA Decay J. Biol. Chem., March 16, 2007; 282(11): 7799 - 7808. [Abstract] [Full Text] [PDF]

				J. Wang, K. Kuropatwinski, J. Hauser, M. R. Rossi, Y. Zhou, A. Conway, J. L.C. Kan, N. W. Gibson, J. K.V. Willson, J. K. Cowell, et al. Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis Mol. Cancer Ther., March 1, 2007; 6(3): 1143 - 1150. [Abstract] [Full Text] [PDF]

				N. Maruyama, Y. Miyoshi, T. Taguchi, Y. Tamaki, M. Monden, and S. Noguchi Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women Clin. Cancer Res., January 15, 2007; 13(2): 408 - 414. [Abstract] [Full Text] [PDF]

				M. P. Hayes, H. Wang, R. Espinal-Witter, W. Douglas, G. J. Solomon, S. J. Baker, and L. H. Ellenson PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia. Clin. Cancer Res., October 15, 2006; 12(20): 5932 - 5935. [Abstract] [Full Text] [PDF]

				G. L. Gallia, V. Rand, I-M. Siu, C. G. Eberhart, C. D. James, S. K.N. Marie, S. M. Oba-Shinjo, C. G. Carlotti, O. L. Caballero, A. J.G. Simpson, et al. PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme Mol. Cancer Res., October 1, 2006; 4(10): 709 - 714. [Abstract] [Full Text] [PDF]

				M. Overholtzer, J. Zhang, G. A. Smolen, B. Muir, W. Li, D. C. Sgroi, C.-X. Deng, J. S. Brugge, and D. A. Haber Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon PNAS, August 15, 2006; 103(33): 12405 - 12410. [Abstract] [Full Text] [PDF]

				A. G. Bader, S. Kang, and P. K. Vogt Cancer-specific mutations in PIK3CA are oncogenic in vivo PNAS, January 31, 2006; 103(5): 1475 - 1479. [Abstract] [Full Text] [PDF]

				S. J. Isakoff, J. A. Engelman, H. Y. Irie, J. Luo, S. M. Brachmann, R. V. Pearline, L. C. Cantley, and J. S. Brugge Breast Cancer-Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells Cancer Res., December 1, 2005; 65(23): 10992 - 11000. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ikenoue, T. Articles by Omata, M. Search for Related Content PubMed PubMed Citation Articles by Ikenoue, T. Articles by Omata, M.